Publication: Kronik myeloid lösemili hastalarda interferon-alfa tedavisine yanıt ve tedaviye bağlı yan etkiller
Abstract
Marmara Üniversitesi Hastanesi hematoloji kliniğinde 3 yıl süresince izlenen 25 kronik faz, kronik myeloid lösemili hastada interferon alfa (INF-α) tedavisine yanıt ve yan etkiler analiz edildi. Ortanca yaşı 37 olan hastaların 17'si kadın, 8'i ise erkekti. Ortalama izlem süresi 17.5 ± 16.5 aydı ve 36 aylık sağkalım %76, hematolojik remisyon %56 oranındaydı. On iki ay ve daha fazla süre INF-α alan hastalarda sitogenetik cevap oranı %33, tam sitogenetik remisyon oranı ise %16.7 olarak gözlendi. Hastaların ancak %12'si başlangıçta hedeflenen 5 milyon Ü/m2/gün dozunu alırken, %60'ı 5 milyon Ü/gün ve %12'si ise 3 milyon Ü/gün dozunda INF-α kullandı. Üç hastada (%12) ise tedaviye bağlı yan etkiler nedeni ile INF-α kesildi. INF-α tedavisi altında gözlenen yan etkiler arasında; 8 hastada nörotoksisite, 8 hastada trombositopeni, 7 hastada poliartralji, 4 hastada büyük eklem artriti, 2 hastada Behçet hastalığı, 1 hastada Coomb's pozitif hemolitik anemi,1 hastada nefrotik sendrom ve 1 hastada membranoproliferatif glomerulonefrit aktivasyonu vardı.
Twenty seven chronic myeloid leukemia patients in chronic phase were analyzed for response to INF-α and its side effects during 3 years of haematology follow-up at Marmara University Hospital. Medyan age of 17 female and 8 male patients was 37 years. Three year survival, with a mean follow-up of 17.5 ± 16.5 months, was 76% and hematological remission was 56%. Complete cytogenetic response was 16.7% and overall cytogenetic response was 33%. Only 12% of patients received pre-planned INF-α dose of 5 million U/m2/day, whereas 60% received 5 million U/day and 2% received 3 million U/day. INF-α treatment was terminated in 3 (12%) patients due to side effects. Among the side effects; neurotoxicity was observed in 8 patients, thrombocytopenia in 8, polyarthralgia in 7, large joint arthritis in 4, Behçet disease in 2, Coombs positive hemolytic anaemia in 1, nephrotic syndrome in 1 and membranoproliferative glomerulonephritis reactivation in 1 patient.
Twenty seven chronic myeloid leukemia patients in chronic phase were analyzed for response to INF-α and its side effects during 3 years of haematology follow-up at Marmara University Hospital. Medyan age of 17 female and 8 male patients was 37 years. Three year survival, with a mean follow-up of 17.5 ± 16.5 months, was 76% and hematological remission was 56%. Complete cytogenetic response was 16.7% and overall cytogenetic response was 33%. Only 12% of patients received pre-planned INF-α dose of 5 million U/m2/day, whereas 60% received 5 million U/day and 2% received 3 million U/day. INF-α treatment was terminated in 3 (12%) patients due to side effects. Among the side effects; neurotoxicity was observed in 8 patients, thrombocytopenia in 8, polyarthralgia in 7, large joint arthritis in 4, Behçet disease in 2, Coombs positive hemolytic anaemia in 1, nephrotic syndrome in 1 and membranoproliferative glomerulonephritis reactivation in 1 patient.